Literature DB >> 18059174

Biology of breast cancer bone metastasis.

Mojtaba Akhtari1, Junaid Mansuri, Kam A Newman, Theresa M Guise, Prem Seth.   

Abstract

Breast carcinoma ranks among the most prevalent malignancies in women. Breast carcinoma frequently metastasizes to bone and approximately 70% of patients with breast cancer have bone metastases, which generally are osteolytic lesions. They cause major morbidity and mortality in patients; and the available treatment options are limited. Bone-specific homing and colonization of cancer cells are important and interesting features of metastasis. There are complex and multiple steps in the process of bone metastasis; and the elaborate interaction between breast carcinoma and bone involves various cytokines, growth factors and cellular signals, which results in a vicious cycle and promotes tumor cell accumulation and osteolysis. Recent advances in molecular biology have resulted in major breakthroughs in our understanding of the pathogenesis of bone metastasis in breast cancer, which is critical in preventing metastasis, designing novel and targeted treatments and prolonging survival in this devastating condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059174     DOI: 10.4161/cbt.7.1.5163

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  51 in total

Review 1.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  TGFβ-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential.

Authors:  Janhavi Gupta; John Robbins; Tamas Jilling; Prem Seth
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

3.  Breast cancer at bone metastatic sites: recent discoveries and treatment targets.

Authors:  Osama Hussein; Svetlana V Komarova
Journal:  J Cell Commun Signal       Date:  2011-01-19       Impact factor: 5.782

4.  Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36).

Authors:  Reyhaan A Chaudhri; Rene Olivares-Navarrete; Natalia Cuenca; Agreen Hadadi; Barbara D Boyan; Zvi Schwartz
Journal:  J Biol Chem       Date:  2012-01-13       Impact factor: 5.157

Review 5.  The botanical molecule p-hydroxycinnamic acid as a new osteogenic agent: insight into the treatment of cancer bone metastases.

Authors:  Masayoshi Yamaguchi
Journal:  Mol Cell Biochem       Date:  2016-08-30       Impact factor: 3.396

6.  Potential suppressive effects of gentian violet on human breast cancer MDA-MB-231 cells in vitro: Comparison with gemcitabine.

Authors:  Masayoshi Yamaguchi; Tomiyasu Murata
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

7.  Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.

Authors:  Arvind K Singla; Alla Bondareva; Frank R Jirik
Journal:  Clin Exp Metastasis       Date:  2014-06-26       Impact factor: 5.150

Review 8.  Optimal management of bone metastases in breast cancer patients.

Authors:  Mh Wong; N Pavlakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-05-02

Review 9.  Parathyroid hormone-related protein: an update.

Authors:  John J Wysolmerski
Journal:  J Clin Endocrinol Metab       Date:  2012-06-28       Impact factor: 5.958

10.  A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.

Authors:  Z Hu; J S Robbins; A Pister; M B Zafar; Z-W Zhang; J Gupta; K J Lee; K Newman; K Neuman; C-O Yun; T Guise; P Seth
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.